FDA Gives Nod to RSV Vaccine for People in Their 50s
MONDAY, June 10, 2024 (HealthDay News) — The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. Drugmaker GSK’s Arexvy vaccine, as well asContinue Reading